Antitumor Activity and Toxicity of Olivamide Dosage Form, a New Semi-Synthetic Olivomycin a Derivative

Abstract

Methods for selective chemical modification of the antibiotic olivomycin A (OA) were developed at G. F. Gause Institute of New Antibiotics. The compound with the highest activity against various tumor cell lines was selected from a series of OA analogs. The aim of the work was to study the antitumor activity and toxicity of a dosage form of this compound, i.e., olivamide. Antitumor activity was studied in four syngenic grafted murine tumors. Chronic toxicity was assessed in experiments with rats that determined the animal body mass, clinical and biochemical blood analysis, urinalysis, electrocardiography, and structures of internal organs. The preparation exhibited high antitumor activity and displayed dose-dependent nephro- and hepatotoxic properties.